Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study
No new safety signals were identified. TTFields+PTX did not significantly improve OS compared with PTX in the intent-to-treat population. An exploratory post-hoc analysis suggests a potentially favorable benefit-risk profile for TTFields therapy in PLD-naive patients.
Authors
- Jalid Sehouli (ORCID: https://orcid.org/0000-0002-5963-6623)
- Antonio González-Martı́n (ORCID: https://orcid.org/0000-0001-8376-9576)
- Hannelore Denys (ORCID: https://orcid.org/0000-0002-8897-9430)
- Radosław Mądry (ORCID: https://orcid.org/0000-0003-0738-2788)
- Bradley J. Monk (ORCID: https://orcid.org/0000-0001-6985-0159)
- David M. O’Malley (ORCID: https://orcid.org/0000-0002-2828-0177)
- Premal H. Thaker (ORCID: https://orcid.org/0000-0002-0568-6959)
- Susie Lau (ORCID: https://orcid.org/0000-0002-4095-1447)
- Giovanni Scambia (ORCID: https://orcid.org/0000-0002-9503-9041)
- Jayanthi Lea (ORCID: https://orcid.org/0000-0002-8657-4309)
- Andrea Bagaméri (ORCID: https://orcid.org/0009-0007-5519-2598)
- Luís Manso (ORCID: https://orcid.org/0000-0002-1683-550X)
- Sabrina Chiara Cecere (ORCID: https://orcid.org/0000-0002-7915-1623)
- Jacob Korach (ORCID: https://orcid.org/0000-0003-0483-4582)
- Martin Hruda (ORCID: https://orcid.org/0000-0002-7606-5164)
- Antonio Ardizzoia (ORCID: https://orcid.org/0000-0003-2232-5677)
- Annouschka Laenen (ORCID: https://orcid.org/0000-0002-1371-442X)
- Viola A Heinzelmann-Schwarz (ORCID: https://orcid.org/0000-0002-5613-8629)
- Ignace Vergote (ORCID: https://orcid.org/0000-0002-7589-8981)
- Larry J. Copeland (ORCID: https://orcid.org/0000-0001-6204-0962)
- Jessica Thomes Pepin
- Regina Berger (ORCID: https://orcid.org/0000-0003-2952-6797)
- David A. Iglesias (ORCID: https://orcid.org/0000-0002-8506-3451)
- David Cibula (ORCID: https://orcid.org/0000-0001-6387-9356)
- Joseph Buscema
- Ayelet Shai (ORCID: https://orcid.org/0000-0001-9502-8441)
- Stéphanie Henry (ORCID: https://orcid.org/0000-0002-4704-4647)
- Toon Van Gorp (ORCID: https://orcid.org/0000-0002-2564-721X)
- Vanda Salutari (ORCID: https://orcid.org/0000-0002-9420-7146)
- Nicoletta Colombo (ORCID: https://orcid.org/0000-0003-2225-715X)
Institutions
- Poznan University of Medical Sciences (PL)
- University of St. Thomas - Minnesota (US)
- Washington University in St. Louis (US)
- Charles University (CZ)
- Sheba Medical Center (IL)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Ghent University Hospital (BE)
- Rambam Health Care Campus (IL)
- Jewish General Hospital (CA)
- University Hospital of Basel (CH)
- Agostino Gemelli University Polyclinic (IT)
- University of Florida (US)
- The European Academy of Gynaecological Surgery (BE)
- CHU Dinant Godinne UCL Namur (BE)
- Southwestern Medical Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Alessandro Manzoni Hospital (IT)
- Florida Cancer Specialists & Research Institute (US)
- National Institute of Oncology (HU)
- Tirol Kliniken (AT)
- Tumour Institute of Tuscany (IT)
- Clinica Universidad de Navarra (ES)
- University Hospital Kralovske Vinohrady (CZ)
- General University Hospital in Prague (CZ)
- Arizona Oncology (US)
- The Ohio State University (US)
- European Institute of Oncology (IT)
- Charité - Universitätsmedizin Berlin (DE)
- The University of Texas Southwestern Medical Center (US)
- UCLouvain (BE)
- KU Leuven (BE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1016/j.ejca.2025.115306
- Citations
- 7
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 11.89
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Teva Pharmaceutical Industries
- F. Hoffmann-La Roche
- Ludwig Institute for Cancer Research
- Regeneron Pharmaceuticals
- Intuitive Surgical
- Exelixis
- Jazz Pharmaceuticals
- Novocure
- Clovis Oncology
- Mersana Therapeutics
- Incyte
- Tarveda Therapeutics
- Seagen
- Eisai
- Swedish Orphan Biovitrum
- PharmaMar
- Genentech
- EMD Serono
- MSD Italia